Read more

April 05, 2024
3 min watch
Save

VIDEO: ‘Clinically meaningful’ topline results from analysis of BE HEARD I, II studies

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN DIEGO — In this Healio video perspective from the American Academy of Dermatology Annual Meeting, Hadar Lev-Tov, MD, shares topline results from an extra analysis of the BE HEARD I and II studies.

The analysis looked at the 1-year follow-up after week 16 of using bimekizumab (Bimzelx, UCB) to treat people with moderate to severe hidradenitis suppurativa.

“Continuous therapy not only improved their pain in a clinically meaningful way, but also allowed them this continuous improvement over time,” Lev-Tov, associate professor of dermatology and cutaneous surgery in the department of dermatology at the University of Miami Miller School of Medicine, told Healio.

“I’m very excited about this because now we’re going to have an option for our patients, hopefully to be approved soon, that will allow us to treat not just the patient’s skin, but also the outcomes that are important to them, namely pain,” he said.